Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-OK

    Ambetter Formulary (Prescription Drug List) - January 2026

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-OK alerts

    Get alerted when Policy AMB25-AHS-C-00023-OK changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Ambetter prescription drug formulary (Prescription Drug List) effective January 1, 2026; it describes covered drugs, tiering, formulary keys/abbreviations, prior authorization process for non-formulary drugs, quantity/age/step-therapy limits and specialty/split-fill handling. Part 1 contains general formulary policies, drug list key definitions, opioid fill limits, and many sample drug entries with tiers and limits (partial list).

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) - January 2026
    Policy CodePolicy AMB25-AHS-C-00023-OK
    Change TypePartial extract / clarifications
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProvider must complete the Prior Authorization form; urgent requests answered within 24 hours and non-urgent within 72 hours of receipt of all necessary information; disapproval notices will state reasons or missing information.
    SourceLink
    POLICY UPDATE CHANGES

    Document is part of Ambetter Formulary Updated January 2026; this part lists tiers, ILimits and PA flags for numerous products.

    ~80+Formulary lines in this partial extract
    multipleEntries requiring PA
    numerousEntries with QL limits
    severalProducts requiring PA (examples)
    partialDocument part

    Coverage summary

    This is a partial extract of the Ambetter Prescription Drug List (Formulary) titled Ambetter Prescription Drug List, effective 2026-01-01. The document presents a mixed coverage stance: many drugs and formulations are listed with tier assignments, utilization-management flags and limits (quantity limits, age limits), and some high-cost or specialty products require specialty handling. This extract focuses on formulary tiering, utilization-management flags and thresholds and specialty handling (partial list of entries and examples).

    Key thresholds & policy info
    Opioid new-start limitNew starts limited to 7-day supply; allow up to two 7-day fills during any 28-day period; up to 28 non-consecutive days in any 90-day period
    Example QL — AdalimumabQL: 0.143 EA daily; many presentations also limited to 1 max fill per 180 days and PA
    Example QL — ActemraQL: 3.6 mL per 28 days (retail); 4 mL per 28 days (mail); SP and PA noted
    Effective dateEffective January 1, 2026
    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) - January 2026
    Policy CodePolicy AMB25-AHS-C-00023-OK
    Change TypePartial extract / clarifications
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProvider must complete the Prior Authorization form; urgent requests answered within 24 hours and non-urgent within 72 hours of receipt of all necessary information; disapproval notices will state reasons or missing information.
    SourceLink
    On This Page
    Coverage summaryPrior authorization & initial coverage criteriaContinuation and utilization flagsNon-formulary, non-covered and exception processFormulary codes and example drug entriesWhat providers must doClinical evidence & definitionsBackground and scopeRevision history
    Policy number
    AMB25-AHS-C-00023-OK
    Scope summaryAmbetter prescription drug formulary listing covered drugs, tiering, QL/AL flags, prior authorization and specialty handling (partial extract)

    Prior authorization & initial coverage criteria

    Prior Authorization for Non-Formulary Drugs

    Prior authorization required for non-formulary drugs; timeframes and notice requirements:

    • Provider action: Provider must complete the Prior Authorization form to request coverage of a non-formulary drug
    • Urgent request response: Urgent requests: services will respond via fax or phone within 24 hours of receipt of all necessary information24 hours

      Response time measured from receipt of all necessary information

    • Non-urgent request response: Non-urgent requests: services will respond via fax or phone within 72 hours of receipt of all necessary information unless state law requires a faster response72 hours

      State law may require faster response

    • Disapproval notice content: If request is disapproved, notice will contain clear explanation of the specific reasons for disapproval or identification of missing material information if incomplete

      Must state reasons or identify missing material information

    Provider summary (policy): Provider must complete the Prior Authorization form; urgent requests answered within 24 hours and non-urgent within 72 hours of receipt of all necessary information; disapproval notices will state reasons or missing information.

    From provider actions summary

    Opioid new-start limits

    Limits for opioids identified on the formulary as 'New starts limited to 7 day supply':

    Opioid new-start enforcement

    • New start supply limit: New starts limited to 7-day supply7 days

      Applies to new opioid starts as identified on formulary

    • 28-day period fills: Allow up to two 7-day fills during any 28-day period2 x 7-day fills per 28 days

      Counts fills within any 28-day period

    • 90-day period cumulative limit: Allow up to a total of 28 non-consecutive days supply in any 90-day period28 days per 90 days

    Formulary Abbreviations and Operational Rules

    Definitions and operational meaning for formulary abbreviations and operational notes:

    Formulary codes - definitions

    • AL (Age Limit): AL = Age Limit; some drugs covered only for certain agese.g., AL(At least N yrs old)

      Examples: AL(At least 2 yrs old); AL(At least 12 yrs old)

    • QL (Quantity Limit): QL = Quantity Limit; some drugs covered only for a certain amountformat QL(x EA daily) or QL(x ML daily) or per fill

      Examples include per day, per fill retail/mail and per X days caps

    • PA (Prior Authorization): PA = Prior Authorization; provider must obtain approval before coverage

    Continuation and utilization flags

    Utilization Management Flags (per drug entry)

    Each drug entry includes one or more of the following utilization management flags:

    Dispensing restrictions example: Some products have maximum fills over specified timeframes (e.g., naloxone retail OTC: 2 max fills per 30 days retail; naltrexone: 3 max fills per 365 days retail/mail); other products show 'Limit 1 fill every 90 days' for select groupsexamples per product row

    Enforced per product and indicated on row

    Formulary coverage entries

    Each drug/class row indicates Tier and any restrictions (quantity limits, PA, SP, fill frequency). Example extracted entries (any of these may appear on a formulary row):

    Example entries (partial)

    • Emtricitabine-tenofovir 100 MG-150 MG: emtricitabine-tenofovir disoproxil fumarate 100 MG-150 MG — Tier 3; QL(1 EA daily)QL(1 EA daily)

      Tier noted as 3 in one entry

    • PIFELTRO (listed near emtricitabine-tenofovir entries) — Tier 3

      Tier shown

    • EMTRIVA SOLN — Tier 3; QL(24 ML daily) (also appears as Tier 1B elsewhere with QL(12 ML))QL(24 ML daily)

      Conflicting tier lines shown in extract

    • FUZEON SOLR — Tier 4; SP; PA

      Special program and prior authorization flags present

    • TRIUMEQ TABS — Tier 3; QL(1 EA daily); TRIUMEQ PD TBSO entry shows PAQL(1 EA daily)

      Some related starter-pack PD entries show PA

    • Hepatitis and CMV agents: CMV and Hepatitis agents often show fill-frequency caps (e.g., Limit 1 fill every 90 days; QL(10 EA per fill retail/mail); 1 max fill per 90 days) and may carry PA/SPe.g., 1 fill per 90 days

      Group-level fill limits shown in extract

    • Cardiovascular agents examples: Many cardiovascular agents show QL per day (e.g., QL(1 EA daily)) and may include D+ or PA flags; examples include verapamil lines and warfarin QL per 180 daysQL per day or per period

      Tier and QL shown on rows

    Operator note: The source presents many per-product rows where Tier, QL, AL, PA, ST, SP and fill-frequency are shown inline; this block preserves the 'any' operator to indicate example coverage rather than exhaustive AND requirements

    Entries are illustrative from the partial extract

    Non-formulary, non-covered and exception process

    Non-formulary (NF) products are not covered unless you or your provider request an exception; providers must complete the Prior Authorization form to request coverage of a non-formulary drug. For non-formulary exception requests the plan will respond to urgent requests within 24 hours and non-urgent requests within 72 hours of receipt of all necessary information; denials will include specific reasons or identification of missing information. Some entries in the formulary are annotated as covered only for specific indications (for example, products marked “Covered for malaria treatment only”) and other products or non‑FDA uses may require prior authorization per the formulary notes.

    Formulary codes and example drug entries

    Formulary tiering (illustrative entries present in part)mixed
    Tier 0No copayment; preventive and mandated products per ACA
    Tier 1ALowest copayment; select high-value drugs and some OTC
    Tier 1BLow copayment; value drugs compared to alternatives
    Tier 2Medium copayment; preferred brand drugs
    Tier 3High copayment; higher-cost brand and non-preferred generics
    Tier 4Specialty tier; specialty/hemophilia network requirements
    Examples of drugs with tier/limits/PANDCCovered
    ENBREL SOSY 25 MG/0.SMLEnbrel subcutaneous (specified strength)
    ANDRODERM PT24 2 MG/24HRTestosterone transdermal patch 2 mg/24 hr
    ANDRODERM PT24 4 MG/24HRTestosterone transdermal patch 4 mg/24 hr
    danazol CAPSDanazol capsules (androgenic agent)
    methyltestosterone TABSMethyltestosterone tablets
    TESTOSTERONE MG/MLTestosterone injection (mg/mL formulations)
    ALPRAZOLAM TABS 0.25/0.5/1/2 MGAlprazolam tablets, multiple strengths
    diazepam (various)Diazepam formulations and strengths
    lorazepam (various)Lorazepam formulations and strengths
    ARNUITY ELLIPTA / fluticasone furoateInhaled corticosteroid product
    1–10 of 13
    1/2
    Opioid-related examplesNDCCovered
    hydromorphone hcl SOLN IJ 10 MG/MLHydromorphone injection 10 mg/mL
    hydromorphone hcl SOLN IJ 50 MG/MLHydromorphone injection 50 mg/mL
    hydromorphone hcl SOLN IJ 500 MG/50MLHydromorphone injection 500 mg/50 mL
    meperidine hcl SOLN IJ 25 MG/MLMeperidine injection 25 mg/mL
    meperidine hcl SOLN IJ 50 MG/MLMeperidine injection 50 mg/mL
    meperidine hcl SOLN IJ 100 MG/MLMeperidine injection 100 mg/mL
    meperidine hcl SOLN PO 50 MG/5MLMeperidine oral solution 50 mg/5 mL
    methadone hcl CONCMethadone concentrated formulation
    methadone hcl SOLN POMethadone oral solution
    methadone hcl SOLN IJ 10 MG/MLMethadone injection 10 mg/mL
    1–10 of 24
    1/3
    Anticoagulants and injectablesNDCCovered
    fondaparinux sodium 10 MG/0.8MLFondaparinux prefilled syringe 10 mg/0.8 mL
    ELIQUIS (apixaban)Apixaban oral anticoagulant (multiple entries)
    rivaroxaban (XARELTO)Rivaroxaban oral anticoagulant (multiple entries)
    enoxaparin sodium SOSY 80 MG/0.8MLEnoxaparin prefilled syringe 80 mg/0.8 mL
    enoxaparin sodium SOSY 120 MG/0.8MLEnoxaparin prefilled syringe 120 mg/0.8 mL
    enoxaparin sodium SOSY 30 MG/0.3MLEnoxaparin prefilled syringe 30 mg/0.3 mL
    enoxaparin sodium SOSY 60 MG/0.6MLEnoxaparin prefilled syringe 60 mg/0.6 mL
    enoxaparin sodium SOSY 100 MG/MLEnoxaparin 100 mg/mL formulation
    enoxaparin sodium SOSY 150 MG/MLEnoxaparin 150 mg/mL formulation
    Seizure and neurology agentsNDCCovered
    VALTOCO 20 MG DOSE / LQPK 10 MG/O.1MLValtoco nasal spray 20 mg and 10 mg per 0.1 mL dose forms
    VALTOCO 5 MG DOSEValtoco 5 mg dose nasal spray
    BANZEL TABS 200 MGRufinamide tablets 200 mg
    BANZEL TABS 400 MGRufinamide tablets 400 mg
    carbamazepine CHEW/CP12/TABS/SUSP/TB12Carbamazepine multiple formulations including chewable and suspension
    DIACOMIT CAPS 250 MGStiripentol (Diacomit) 250 mg capsules
    DIACOMIT CAPS 500 MGStiripentol 500 mg capsules
    rufinamide SUSPRufinamide suspension
    rufinamide TABS 200 MGRufinamide tablets 200 mg
    rufinamide TABS 400 MGRufinamide tablets 400 mg
    1–10 of 20
    1/2
    Psychiatric and CNS agentsNDCCovered
    SSRIs: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertralineSelective serotonin reuptake inhibitors (multiple formulations and strengths)
    SNRIs and desvenlafaxine/duloxetineSerotonin-norepinephrine reuptake inhibitors and related agents
    POMALYSTPomalidomide (antineoplastic immunomodulator) - specialty handling
    FANAPT TITRATION PACK AIloperidone titration pack
    risperidone (microspheres/SOLN/TABS/TBDP)Risperidone multiple formulations including long-acting injection
    Antiemetics and supportive careNDCCovered
    ANZEMETDolasetron (5-HT3 antagonist)
    granisetronGranisetron (5-HT3 antagonist)
    ondansetronOndansetron (5-HT3 antagonist)
    LIQD naloxoneNaloxone liquid formulations
    SOLN 0.4 MG/ML naloxoneNaloxone 0.4 mg/mL solution
    4 MG/10ML naloxoneNaloxone 4 mg per 10 mL formulation
    Oncology agents and categories (selected entries)NDCCovered
    GLEOSTINE 100 MGLomustine 100 mg capsules
    ifosfamide SOLN 1 GM/20MLIfosfamide solution 1 g/20 mL
    oxaliplatin SOLN 100 MG/20MLOxaliplatin solution 100 mg/20 mL
    clofarabineClofarabine formulations
    decitabineDecitabine formulations
    floxuridineFloxuridine formulations
    fludarabine phosphate SOLNFludarabine phosphate solution
    fluorouracil 500 MG/10ML5-FU 500 mg/10 mL vial
    VECTIBIX 100 MG/5MLPanitumumab 100 mg/5 mL
    VIZIMPRODacomitinib
    1–10 of 26
    1/3
    Antiparkinson, movement disorder, and akinetic agentsNDCCovered
    benztropine mesylateBenztropine formulations
    selegiline hcl CAPSSelegiline capsules
    trihexyphenidyl hcl SOLN/TABSTrihexyphenidyl solution and tablets
    amantadine hcl CAPS/SOLN/TABSAmantadine across formulations
    bromocriptine mesylate CAPS/TABSBromocriptine formulations
    carbidopa-levodopa TABS/TBCR/TBDPCarbidopa-levodopa multiple formulations
    HIV and antiviral agents (selected combos)NDCCovered
    COMPLERAEmtricitabine-rilpivirine-tenofovir DF combination
    emtricitabine-rilpivirine-tenofovir disoproxil fumarateCombination product entries
    efavirenzEfavirenz formulations and doses
    etravirine 100/200 MGEtravirine tablet strengths
    Diabetes and combination therapiesNDCCovered
    GLYXAMBIEmpagliflozin/linagliptin
    JANUMET XR/TABSSitagliptin/metformin extended release
    pioglitazone combosPioglitazone combination products
    saxagliptin-metforminSaxagliptin/metformin combination
    SOLIQUAInsulin glargine/lixisenatide combination
    SYNJARDY XR/TABSEmpagliflozin/metformin XR
    TRIJARDY XRMetformin/empagliflozin/linagliptin triple combo
    Insulins and concentrated insulinsNDCCovered
    HUMULIN R U-500 CONCENTRATED SOLN SC / KWIKPENHuman insulin U-500 concentrated formulations
    INSULIN ASPARTInsulin aspart products
    INSULIN GLARGINEInsulin glargine products
    INSULIN LISPROInsulin lispro products
    NOVOLINNovolin insulin products
    NOVOLOGNovolog insulin products
    Antibiotics, antiretrovirals, and broad alphabetical entriesmixed
    abacavir sulfate SOLN/TABSAbacavir formulations
    abiraterone acetate 250 MGAbiraterone 250 mg
    abiraterone acetate 500 MGAbiraterone 500 mg
    many alphabetical entries (acamprosate, acarbose, acebutolol, etc.)Comprehensive alphabetical listing included in full formulary
    Remaining specialty and therapeutic classes (groups)mixed
    Antineoplastic Hormonal and Related AgentsGroup listing - see formulary for specifics
    Antineoplastic ImmunomodulatorsGroup listing - see formulary for specifics
    Antineoplastic AntibioticsGroup listing - see formulary for specifics
    Antineoplastic Enzyme InhibitorsGroup listing - see formulary for specifics
    Antineoplastic CombinationsGroup listing - see formulary for specifics
    Topoisomerase InhibitorsGroup listing - see formulary for specifics

    What providers must do

    Prior Authorization

    Prior authorization for non-formulary drugs

    Prior authorization is required for non-formulary drugs. Providers must submit a completed Prior Authorization form. Urgent requests will be responded to within 24 hours of receipt of all necessary information; non-urgent requests within 72 hours, unless state law requires a faster response. If a request is disapproved, the notice of disapproval will include a clear explanation of the specific reasons or, if incomplete, identify the missing material information needed to complete the request.

    • Provider must complete and submit the PA form for NF drugs.
    • Response timelines: 24 hours for urgent requests; 72 hours for non-urgent requests (state law may require faster).
    • Disapproval notices must state specific reasons or missing information.
    Prior Authorization

    Prior authorization for certain formulary products

    Prior authorization is required for certain formulary specialty and higher-cost products. Providers should check formulary flags (PA) for listed agents and submit PA when indicated.

    • Examples of products commonly requiring PA or special handling: adalimumab products (multiple entries), ARIKAYCE, ACTEMRA, ENBREL, OTEZLA.
    • Many specialty and injectable biologics have PA flags — verify per-drug requirements prior to dispensing.
    Billing Rule

    Opioid new-start quantity enforcement

    New-start opioid fills and ongoing opioid quantity are limited. Limits are enforced at point-of-sale; providers may request prior authorization for medically necessary exceptions. Requests for fills exceeding limits may be denied if not supported.

    • New starts are limited to a 7-day supply.
    • Allow up to two 7-day fills during any 28-day period (i.e., two short fills permitted in a 28-day window).
    • Total allowed: up to a cumulative 28-day supply (non-consecutive) in any 90-day period across all opioid medications.
    • For fills exceeding these limits, providers may submit a Prior Authorization request for exceptions.
    • Exceeding the limits without an approved PA risks claim denial.
    Documentation Required

    Specialty drug fulfillment

    Certain products are designated Specialty (SP) and may require fulfillment via the plan's specialty or hemophilia network pharmacies. Specialty handling and SP designation may also trigger PA, limited distribution, or special clinical management requirements.

    • Specialty drugs may require dispensing by a participating specialty network pharmacy.
    • SP-designated agents frequently include oncology biologics, injectable biologics, and complex therapies.
    • Example agents noted with SP considerations: oncology biologics, FUZEON, treprostinil.
    • Providers should verify specialty pharmacy requirements and preferred vendors before prescribing/dispensing.
    Billing Rule

    Quantity limits enforcement

    Quantity limits are enforced per-day, per-fill, or per-specified-interval and will be applied at point-of-sale. Excess quantities may be denied or require prior authorization; providers should document medical necessity when requesting exceptions.

    • Quantity limit formats include per-day caps, per-fill maximums, and interval-based totals (e.g., 28-day, 90-day windows).
    • Examples of enforced limits: warfarin, enoxaparin, and naloxone have specified QLs or limits noted on the formulary.
    • OTC vs Rx distinction: naloxone coverage and limits may vary by OTC vs prescription presentation — verify formulary entry before dispensing.
    • Exceeding documented QLs at point-of-sale may be denied or require PA and supporting documentation.
    • Providers must follow formulary tier and QL rules and submit PA with documentation when seeking coverage beyond limits.
    Step Therapy

    Step therapy applies

    Step therapy (ST) requirements apply to selected products. When ST is in effect, members must try designated preferred alternatives (steps) before higher-tier or non-preferred products will be covered. Providers may request an exception or submit documentation showing why step requirements should be waived.

    • Step therapy applies to certain products and will map to preferred alternative agents as specified on the formulary.
    • When an ST flag is present, coverage for the requested drug may require prior trial and failure of the preferred agent(s).
    • Providers should reference product-level ST mappings on the formulary and document prior therapy or medical rationale when requesting PA or exceptions.
    Documentation Required

    Age and indication documentation

    Age limits and indication documentation are required for some drugs. Providers must document patient age and clinical indication to support coverage when AL or indication-based restrictions are present.

    • Age limits (AL) apply to select products — coverage may be restricted to specified age ranges.
    • Examples: some topical antifungals (e.g., miconazole) and certain estradiol vaginal products have age-related notes or indication limits.
    • Providers must document age and clinical indication in the PA or claims record to support coverage and avoid denials.
    Documentation Required

    Non‑FDA uses require documentation / PA

    Non‑FDA (off‑label) uses frequently require documentation and may require prior authorization. Provide clinical rationale, supporting literature, and pertinent patient history when seeking coverage for non‑FDA indications.

    • Non‑FDA uses require documentation and often a PA.
    • Examples include pancreatic enzyme replacements such as CREON and ZENPEP when used for indications not explicitly FDA‑labeled.
    • Clinical notes, diagnoses, and prior therapy history should accompany PA requests for off‑label uses.

    Clinical evidence & definitions

    Definitions and abbreviations used in the formulary extract (as presented in the document): AL = Age Limit (some drugs only covered for certain ages); QL = Quantity Limit (limits on amount dispensed per day, per fill, or per period); PA = Prior Authorization (pre-approval required before coverage); ST = Step Therapy (required prior trials before coverage); SP = Specialty Drug (may require specialty pharmacy fulfillment); SF = Split Fill (initial 15-day increments until stabilized); NF = Non‑formulary (not covered unless exception requested); RX/oTC = prescription and over‑the‑counter forms. No clinical trials or evidence summaries are included in this part of the extract.

    Background and scope

    Background: The Ambetter Formulary guides covered brand and generic drugs under the prescription drug benefit. Generic drugs are preferred first-line when available; preferred brand drugs are identified on lower tiers when clinically appropriate. The Formulary is periodically reviewed and may change; not all strengths or dosage forms may be covered. Plan-specific benefit designs may impose additional coverage limits or different cost sharing. This output is a partial extract of the Ambetter Formulary (January 2026).

    Known data quality issues in this extract: entries are fragmented in places, tier mappings and flag placements may be inconsistent across lines, and there are formatting artifacts (e.g., corrupted fields and 'prug Name' mapping artifacts). Consult the full Ambetter formulary or the payer for authoritative coding, exact benefit coverage, and limits before making coverage or billing decisions.

    Revision history

    2026-01-01partial_extractLatest

    Partial extract (part 3 of 15) from Ambetter Formulary Updated January 2026 — this segment lists tiers, quantity limits (QL), age limits (AL), prior authorization (PA), specialty (SP) flags and fill-frequency constraints for numerous products; no explicit revision history present in this segment.

    Non-consecutive days count toward 28-day cap

  1. Cumulative across opioids: Limit applies cumulatively to all opioid medications filled

    Applies across opioid products/classes

  2. Prior Authorization for exceptions: For fills exceeding these limits, provider may submit a Prior Authorization request

    Exceptions processed via PA

  3. Opioid claim enforcement note: Claims for opioid new-start fills exceeding 7-day limits (or cumulative limits: two 7-day fills per 28 days; 28 days per 90 days) may be denied unless a prior authorization is submitted.

    From provider actions summary

    Provider must submit PA when product flagged PA

  4. ST (Step Therapy): ST = Step Therapy; member must try specified drugs first before coverage of others

    May require trial of preferred agents first

  5. NF (Non-Formulary): NF = Non-formulary; not covered unless exception requested

    Exception via prior authorization

  6. RX/oTC = Prescription and OTC; drug may be available as prescription or over-the-counter

    Plan may designate OTC vs Rx rules (e.g., naloxone)

  7. SP (Specialty): SP = Specialty Drug; may have special fill requirements and specialty pharmacy network fulfillment

    Specialty-tier drugs may require specialty pharmacy

  8. SF (Split Fill): SF = Split Fill; initial fills may be 15-day increments until stabilized (restriction may lift after 90 days)15-day increments initially; restriction may lift after 90 days

    Operational split-fill rule

  9. D/D+/c = indicates alternative copays for certain benefit designs; consult benefit documents

    Not applicable for some plans; consult benefit documents

  10. Formulary operational note: Brand and generic tiering is used; specialty-tier drugs may require fulfillment at participating specialty or hemophilia network pharmacies; the formulary is periodically reviewed and may change

    See formulary overview and Drug List Key